Results 261 to 270 of about 2,507,641 (307)

Associations between pretreatment composite inflammatory indices and pathological response to neoadjuvant therapy in breast cancer: a retrospective cohort study. [PDF]

Front Oncol
Zhang Y, Tong C.
europepmc   +1 more source

The impact of HER2 discordance on patient prognosis following anti-HER2 neoadjuvant therapy for HER2-positive breast cancer. [PDF]

Front Oncol
Ren Y, Su T, Gong Z, Li G, Feng H, Feng X, Zhou S, Xing W.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Neoadjuvant Therapy for Breast Cancer

Annual Review of Medicine, 2015
Neoadjuvant treatment of breast cancer refers to the use of different treatment modalities prior to surgical excision of the tumor. It has been accepted as a treatment option for patients with nonmetastatic disease, because it renders inoperable tumors operable and increases the rates of breast-conserving surgery, while achieving similar long-term ...
Martine Piccart, Dimitrios Zardavas
exaly   +3 more sources

Neoadjuvant Therapy for Melanoma

Surgical Oncology Clinics of North America, 2020
With the universal adoption of immune checkpoint blockade and agents targeting BRAF-mutated melanomas in the metastatic setting, numerous clinical trials have evaluated these agents in the neoadjuvant setting. These smaller trials have shown promising results with high pathologic response rates and acceptable safety.
Michael C, Lowe, Ragini R, Kudchadkar
openaire   +2 more sources

Neoadjuvant therapy for pancreatic cancer

Nature Reviews Clinical Oncology, 2023
Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with surgical resection of the primary tumour and systemic chemotherapy, which provides considerably longer overall survival (OS) durations than either modality alone. Regardless, most patients will have disease relapse owing to micrometastatic disease.
Christoph Springfeld, Cristina R. Ferrone, Matthew H. G. Katz, Philip A. Philip, Theodore S. Hong, Thilo Hackert, Markus W. Büchler, John Neoptolemos   +7 more
openaire   +2 more sources

Neoadjuvant Therapy for Rectal Cancer

Surgical Oncology Clinics of North America, 2022
The treatment of locally advanced rectal cancer is challenging and requires a multidisciplinary approach. Neoadjuvant treatment has improved local control by the combination of radiotherapy, surgery, and chemotherapy. However, neoadjuvant treatment has not yet been shown to improve overall survival and is associated with toxicities and late sequelae ...
Felipe F, Quezada-Diaz, J Joshua, Smith
openaire   +2 more sources

Neoadjuvant Therapy in Esophageal Cancer

Thoracic Surgery Clinics, 2022
Locally advanced esophageal cancer has a dismal prognosis. Surgery remains the cornerstone treatment with 5-year survival rates of approximately 12-39%. Rates of local failure and distant metastases are high following surgical resection of locally advanced tumors.
Shirley, Lewis, Jelena, Lukovic
openaire   +2 more sources

Neoadjuvant Therapy in Pancreatic Cancer

Cancer Investigation, 2007
Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. Surgical resection offers the only hope of cure, though the addition of chemoradiation in the adjuvant setting has been shown to improve survival over surgery alone. Many patients are unable to receive adjuvant therapy due to prolonged postoperative recovery.
Roderick M, Quiros, Kimberly M, Brown, John P, Hoffman   +2 more
openaire   +2 more sources

Neoadjuvant Therapy of Esophageal Cancer

Surgical Oncology Clinics of North America, 1997
Locally advanced esophageal cancer, potentially curable with surgery or radiotherapy-based treatment, has a poor prognosis because of the eventual development of systemic metastatic disease in the majority of patients. Local recurrence of disease after local treatment modalities is equally problematic.
D H, Ilson, M, Bains, R J, Ginsberg, D P, Kelsen   +3 more
openaire   +2 more sources

Neoadjuvant Therapy in Rectal Cancer

Diseases of the Colon & Rectum, 2011
The optimal type of neoadjuvant therapy regimen in rectal cancer is contentious.This study aimed to review the impact of neoadjuvant therapy on oncological outcomes and complications (short and long term) in patients undergoing total mesorectal excision for rectal cancer.An electronic search of MEDLINE, PubMed, EMBASE, and the Cochrane Database of ...
Fergal J, Fleming, Lars, Påhlman, John R T, Monson   +2 more
openaire   +2 more sources